» Articles » PMID: 28988454

Awake Serial Intralesional Steroid Injections Without Surgery As a Novel Targeted Treatment for Idiopathic Subglottic Stenosis

Overview
Journal Laryngoscope
Date 2017 Oct 9
PMID 28988454
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives/hypothesis: The fibrotic/erythematous appearance of the subglottis in idiopathic subglottic stenosis (iSGS) hints that it might respond to repeated intralesional steroid treatment similar to keloids.

Study Design: Retrospective cohort study.

Methods: Thirteen iSGS subjects (six treated in-office with serial intralesional steroid injections [SILSI] versus seven treated endoscopically in the operating room [OR] followed by awake SILSI) between October 2011 and April 2017. Forced spirometry was performed before injections and at each follow-up visit (peak expiratory flow [%PEF] and peak inspiratory flow). Steroids were injected via transcricothyroid or transnasal routes. Injections were grouped into rounds of four to six injections separated by 3 to 5 weeks.

Results: Thirteen subjects with a mean follow-up of 3 years (3.3 years for SILSI and 2.7 years for OR). Awake-only SILSI subjects had a mean improvement/round of 23.1% %PEF (range, 65.4%-88.6%), whereas the OR-treated subjects had a mean %PEF improvement/round of 25.1% (range, 57.4%-82.5%). Both groups had improved breathing, and the improvements were statistically equal (P = .569). SILSI subjects underwent 5.3 injections/round in 1.3 rounds, whereas OR subjects had 5.9 injections/round over 2.1 rounds. Statistically significant improvement was seen in %PEF for both groups (SILSI P = .007, OR P = .002). Overall, SILSI achieved sustained %PEF above 80% in 83% (5/6) and OR + SILSI 86% (6/7).

Conclusions: SILSI in the awake outpatient setting can improve the airway caliber in iSGS and is equivalent to endoscopic OR treatment. We believe iSGS can be viewed as a chronic scarring/inflammatory condition that can benefit from steroid scar-modification therapy.

Level Of Evidence: 4. Laryngoscope, 128:610-617, 2018.

Citing Articles

In-office serial intralesional steroid injection for subglottic stenosis: Case series of 14 patients with multiple etiologies.

Wehbi N, Gleadhill C, Ahmadian D, Skirko J, Yip H World J Otorhinolaryngol Head Neck Surg. 2025; 11(1):17-22.

PMID: 40070504 PMC: 11891261. DOI: 10.1002/wjo2.159.


Comparing Intraoperative and In-Office Steroid Injections for Management of Subglottic Stenosis.

Ramazani F, Bosch J, Randall D Laryngoscope. 2024; 135(4):1438-1443.

PMID: 39520252 PMC: 11903925. DOI: 10.1002/lary.31903.


Local adjuncts to minimally invasive endoscopic interventions for benign laryngotracheal stenosis: a meta-analysis.

Ming W, Zuo J, Han J, Chen J Eur Arch Otorhinolaryngol. 2024; 281(10):5395-5410.

PMID: 38967672 DOI: 10.1007/s00405-024-08810-x.


Volume and Practice-Setting Shift of Laryngology Procedures During the COVID-19 Pandemic: A Reg-ENT Database Analysis.

Gray R, Ryan M, Mehta V OTO Open. 2024; 8(2):e128.

PMID: 38590586 PMC: 11000131. DOI: 10.1002/oto2.128.


Drug delivery systems for wound healing treatment of upper airway injury.

Cruz D, Zheng A, Debele T, Larson P, Dion G, Park Y Expert Opin Drug Deliv. 2024; 21(4):573-591.

PMID: 38588553 PMC: 11208077. DOI: 10.1080/17425247.2024.2340653.